PMID- 17343331
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20070308
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 10
IP  - 2
DP  - 2005 Apr-Jun
TI  - The results of concomitant and sequential chemoradiotherapy with cisplatin and 
      etoposide in patients with locally advanced non-small cell lung cancer.
PG  - 213-8
AB  - PURPOSE: To report on the treatment results and demographic characteristics of 
      patients with locally advanced non small cell lung carcinoma (NSCLC) who were 
      treated with concomitant or sequential chemoradiotherapy. PATIENTS AND METHODS: 
      132 patients with locally advanced NSCLC (stage IIIB) were evaluated. Their 
      median age was 60 years (range 33-80). Histopathological diagnosis was epidermoid 
      carcinoma in 96 (73%) patients, adenocarcinoma in 33 (25%) patients and large 
      cell carcinoma in 3 (2%) patients. Karnofsky performance status (KPS) score was 
      >/= 70 in 112 (85%) patients. Weight loss was greater than 5% in 34 (26%) 
      patients at presentation. One hundred and six (80%) patients were treated with 
      sequential chemoradiotherapy which consisted of 3 monthly cycles of cisplatin 
      (100 mg/m(2), day 1) and etoposide (100 mg/m(2)/day, days 1-3) before 
      radiotherapy. Radiotherapy consisted of a total dose of 60 Gy in 30 fractions (2 
      Gy / fraction), given to a volume including primary tumor and mediastinum. Two to 
      4 cycles of chemotherapy were administered after completion of radiotherapy to 
      patients whose disease had not progressed after initial chemotherapy. Twenty-six 
      patients were treated with concomitant chemoradiotherapy. The same radiotherapy 
      regimen was started with the 2nd cycle of chemotherapy which consisted of 
      cisplatin (80 mg/m(2), day 1) and etoposide (100 mg/m(2)/day, days 1-3). 
      Chemotherapy was completed after 4 cycles in all patients. RESULTS: Overall 
      survival (OS) was 14.5 months in 106 patients treated with sequential 
      chemoradiotherapy and 14.6 months in 26 patients treated with concomitant 
      chemoradiotherapy (p=0.99). Median time to progression was 9.77 months in the 
      concomitant group and 11.6 months in the sequential group (p=0.47). However, 
      progression-free survival was better in patients of both groups whose KPS was >70 
      (12.4 months versus 11.5 months, p= 0.02). While presence of anemia was found as 
      an adverse prognostic factor only in univariate analysis, non-epidermoid 
      histology, KPS less than 70 and presence of N2-N3 disease were found as adverse 
      prognostic factors in both univariate and multivariate analysis. CONCLUSION: The 
      addition of chemotherapy to radiation concomitantly or sequentially prolongs 
      survival in locally advanced NSCLC patients with acceptable adverse event 
      profiles in both arms compared with results of the trials in the literature in 
      which radiotherapy is used as single treatment modality.
FAU - Saynak, M
AU  - Saynak M
AD  - Radiotherapy Department, Selcuk University, Meram Faculty of Medicine, Konya, 
      Turkey.
FAU - Aksu, G
AU  - Aksu G
FAU - Fayda, M
AU  - Fayda M
FAU - Kaytan, E
AU  - Kaytan E
FAU - Oral, E
AU  - Oral E
FAU - Gurocak, S
AU  - Gurocak S
FAU - Kizir, A
AU  - Kizir A
FAU - Karadeniz, A
AU  - Karadeniz A
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
EDAT- 2007/03/09 09:00
MHDA- 2007/03/09 09:01
CRDT- 2007/03/09 09:00
PHST- 2007/03/09 09:00 [pubmed]
PHST- 2007/03/09 09:01 [medline]
PHST- 2007/03/09 09:00 [entrez]
PST - ppublish
SO  - J BUON. 2005 Apr-Jun;10(2):213-8.